How Semaglutide Promotes Bone Formation by Activating Stem Cells in the Jaw: A Mechanistic Study in Rats | Research

The takeaway

Semaglutide (a GLP-1 receptor agonist) significantly improved osteoporosis in rats by enhancing jawbone stem cell differentiation into bone-forming cells through two distinct signaling pathways.

Dual Pathway Mechanism
Semaglutide promotes bone formation through two pathways: one directing stem cells to become bone-building cells, another keeping stem cells healthy and proliferating

What the researchers found

Semaglutide significantly ameliorated osteoporosis in rats when combined with jaw bone marrow mesenchymal stem cell (JBMMSC) intervention. The drug markedly increased calcified nodule formation and alkaline phosphatase (ALP) activity, demonstrating enhanced osteogenic potential.

Mechanistically, semaglutide operates through dual pathways: (1) promoting osteogenic and adipogenic differentiation via the BMP2/STAT3/TET3/SHP2 signaling axis, and (2) preserving stem cell stemness and proliferation via the CREB/YAP/BRD4 axis. Western blot analysis confirmed significant upregulation of p-CREB, OCT4, BMP2, and RUNX2 proteins in semaglutide-treated JBMMSCs. These mechanisms were validated by rescue experiments, confirming the dual pathway model.

Why it matters

GLP-1 receptor agonists like semaglutide are already prescribed to millions for obesity and diabetes. If they also protect and regenerate bone, this could be a significant added benefit — especially since osteoporosis is common in the same aging populations that use these drugs. Jaw osteoporosis specifically affects dental implant success and oral health in elderly patients, making this a practically relevant finding.

How the study worked

The study used both bioinformatics analysis (GEO database) and experimental approaches. JBMMSCs were isolated from rat mandibles and characterized by flow cytometry. In vivo, stem cells were injected via tail vein into osteoporotic rat models and assessed with HE staining. In vitro, optimal semaglutide concentrations were determined using CCK-8 viability, colony formation, and scratch migration assays. Osteogenic differentiation was assessed by ALP and Alizarin Red S staining; adipogenic differentiation by Oil Red O staining. Molecular signaling was analyzed by Western blotting and immunofluorescence.

What this study cannot tell us

This is an animal study in rats, and jaw bone biology in rats differs from humans. The osteoporosis model may not fully replicate human disease. The stem cell tail vein injection approach is not a standard clinical practice. Specific quantitative data on bone density improvement or sample sizes were not provided in the abstract. Long-term effects and optimal dosing for bone applications remain unknown.

How to read the evidence

This is a preclinical animal study with in vitro mechanistic work. While it provides detailed molecular mechanisms validated by rescue experiments, the findings are from rats and have not been confirmed in humans. This represents early-stage evidence requiring clinical translation.

When this study was published

Published in 2025, this is very recent research exploring the bone-protective effects of GLP-1 receptor agonists — a rapidly expanding area of investigation as these peptide drugs see unprecedented clinical use.

The bigger picture

This study adds to the growing evidence that GLP-1 peptide drugs have effects far beyond blood sugar and weight — including bone health, cardiovascular protection, and neuroprotection. Understanding the precise molecular mechanisms by which semaglutide promotes bone formation could lead to optimized peptide therapies specifically designed for osteoporosis, or at minimum, help clinicians understand the full spectrum of benefits when prescribing these drugs.

Questions still open

Do patients taking semaglutide for obesity or diabetes show measurable improvements in bone density as a secondary benefit?
Could GLP-1 receptor agonists be developed specifically for osteoporosis treatment, particularly in the jaw for dental implant patients?
How do the bone-forming effects of semaglutide compare to established osteoporosis treatments like bisphosphonates?

Common questions

Could semaglutide (Wegovy/Ozempic) help treat osteoporosis?

This rat study suggests it's possible. Semaglutide promoted bone formation by activating stem cells in the jaw through two molecular pathways. However, this has only been shown in animal experiments — human clinical trials would be needed before GLP-1 drugs could be recommended for osteoporosis. Patients currently taking semaglutide for weight loss or diabetes may see some bone benefits, but this hasn't been confirmed clinically.

What are jaw bone marrow mesenchymal stem cells?

These are adult stem cells found in the bone marrow of the jaw that can develop into various cell types, including bone-forming cells (osteoblasts) and fat cells (adipocytes). In this study, semaglutide enhanced these stem cells' ability to form bone while maintaining their capacity to proliferate, suggesting that GLP-1 receptor agonists could support jaw bone health — particularly relevant for dental implant patients and those with jaw osteoporosis.

Read the original research

GLP-1RA in JBMMSCs promoted osteogenic differentiation via modulating CREB and BRD4 signaling mediated proliferation and stemness.

Scientific reports, 15(1), 40773

View on PubMed ↗Publisher’s paper ↗

Citation

Liu, Huiming; Tian, Yawei; Bao, Xiaoxue; Li, Yukun. (2025). GLP-1RA in JBMMSCs promoted osteogenic differentiation via modulating CREB and BRD4 signaling mediated proliferation and stemness.. Scientific reports, 15(1), 40773. https://doi.org/10.1038/s41598-025-24633-0